Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 56%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is expected to see strong performance in both their immunology and oncology franchises, as well as their aesthetics business thanks to key products like Humira, Skyrizi, Botox, and Imbruvica. The recent acquisitions of Allergan, Cerevel, and ImmunoGen also add to AbbVie's diverse and growing portfolio. Upcoming catalysts, such as potential FDA approvals and new clinical data, could also drive future growth for the company. While there may be some potential risks, such as disappointing clinical data or macroeconomic challenges, AbbVie's strong pipeline and diverse offerings make it a promising investment opportunity.

Bears say

AbbVie is showing strong performance in its key drivers and has a robust pipeline with the recent acquisitions of Cerevel and ImmunoGen. However, there are still risks to the stock, such as potential challenges with commercial execution, disappointing clinical data or regulatory setbacks, and macroeconomic challenges in Aesthetics. Overall, the financial model has been moderately adjusted and the company's solid 1Q 2026 results suggest potential for continued success, but potential risks should still be considered.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 56% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $256.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $256.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.